The European Commission has approved Dova Pharmaceuticals' Doptelet, or avatrombopag, for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who require an invasive procedure.
MEI Pharma provided updated data on a Phase Ib trial assessing its PI3K delta inhibitor ME-401 in combination with either Roche's Rituxan, or rituximab, or BeiGene's zanubrutinib as a treatment for relapsed/refractory lymphocytic leukemia or small lymphocytic lymphoma and relapsed/refractory follicular lymphoma. Results presented at the International Conference on Malignant Lymphoma showed an 83% overall response rate was achieved in the 64-patient cohort while a 100% response rate was induced in all CLL/SLL participants.
KB103, Krystal Biotech's lead gene therapy for recessive dystrophic epidermolysis bullosa, exhibited efficacy in healing wounds caused by the disorder after it reported full closure of five lesions by the 90th day after treatment based on data from its Phase I/II GEM trial. Krystal also disclosed that KB103 has been granted a regenerative medicine advanced therapy designation by the FDA.
Bristol-Myers Squibb said that it would sell off Celgene's psoriasis drug Otezla to address concerns about competition the Federal Trade Commission had raised in connection to the company's planned $74 billion Celgene acquisition, which is anticipated to close later than initially expected.
Sanifit will advance its SNF472, indicated to treat rare vascular calcification disorder calciphlaxis, into late-stage testing using $82.1 million cash funding, including a $62.8 million from a Series D funding.
The Chan Zuckerberg Biohub, supported by financing from the Bill and Melinda Gates Foundation, will fund studies that will advance infectious disease metagenomic sequencing in 10 international countries. The Biohub has developed an open-source, cloud-based pipeline called ID-seq used for pathogen detection and surveillance.
The Department of Defense has awarded Hillrom subsidiary Welch Allyn a $100 million contract to provide the Army, Navy, Marine Corps, Air Force and federal civilian agencies with patient monitoring equipment. Thirty-six companies competed for the five-year contract, which comes with a five-year option after June 24, 2024.
Conformis has secured a $20 million term loan and a $10 million credit revolver from Innovatus Capital Partners and East West Bank, as well as equity financing worth $3 million from Innovatus. The debt financing proceeds will be used for paying off a term loan with Oxford Finance.
A round of Series B financing involving Boston Scientific and other investors has brought in $15 million for startup InterVene, which makes the BlueLeaf Endovenous Valve Formation System for treating deep vein reflux. The company will use the proceeds for clinical research program expansion as well as for US trials via an investigative device exemption.
- Page 1